Genmab — April 2020

[E_L]

or maybe i should call it by it's
new name, Talquetamab

[Sukkeralf]

otherwise we dont know what you re talking about

[Sukkeralf]

When do we get some more serious milestones from the JNJ DuoBody collaboration

[E_L]

lol, the article is fortunately really easy to read #not...

[E_L]

you are correct, some milestones would be really nice, unfortunately we will not get them for articles... we also don't get them for going into the clinic, nor for getting a Breakthrough Therapy Designation ... maybe we have to wait for an approval

[Sukkeralf]

no that would be too easy - sales sales sales

[Sukkeralf]

No of course these deals are backloaded but at least a small appreciation for things moving forward would be
nice

[GeorgeBest]

JNJ-372 is the most advanced Janssen duobody. Any idea when this (if successful) coole

[GeorgeBest]

Any idea when this could generate any Sales?

[Sukkeralf]

Not exactly - but maybe something like 2023-2026 for the first DuoBodies

[E_L]

i only know last year JNJ included it in a slide saying potential filing 2019-2023 (also JNJ 7957 and 7564)

[Bulder]

Didn't know that Talquetamab is tested in combo with dara. https://www.clinicaltrials.gov/ct2/show/NCT04108195?term=daratumumab+talquetamab&draw=2&rank=1

[GeorgeBest]

Thanks mates. If its 2023 its not that far away. I also remember it was once mentioned that JNJ expect 3 of the Genmab duobodies to have blockbuster potential

[E_L]

yes, for the 3 mentioned above

[Helge_LarsenPI-redaktør]

God morgen.

[E_L]

Few comments on the MASTER trial: Impact of autologous hematopoietic cell transplant on measurable MRD in the setting Dara-KRd https://www.ascopost.com/issues/april-10-2020/highlights-from-transplantation-and-cellular-therapy-meetings-of-astct-and-cibmtr/

[Helge_LarsenPI-redaktør]

God morgen

[Helge_LarsenPI-redaktør]

Test

[AaBforever]

Det er da gået helt i stå her på chatten!!

[AaBforever]

Hvad mener folket om salget af dara i Q1 når JnJ aflægger regnskab i morgen?